Toxic epidermal necrolysis and hemophagocytic lymphohistiocytosis: a case report and literature review

Jonathan D. S. Sniderman¹, Geoff D. E. Cuvelier¹², Stasa Veroukis¹³ & Gregory Hansen¹³

¹Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada
²Pediatric Hematólogy-Oncology-BMT, CancerCare Manitoba, Winnipeg, Manitoba, Canada
³Pediatric Intensive Care, Winnipeg Children’s Hospital, Winnipeg, Manitoba, Canada

Key Clinical Message
Diagnostic criteria for hemophagocytic lymphohistiocytosis should be reviewed early in critically ill patients with toxic epidermal necrolysis, multisystem dysfunction, and a deteriorating clinical trajectory.

Keywords
Critical illness, hemophagocytic lymphohistiocytosis, toxic epidermal necrolysis.

Introduction
Toxic epidermal necrolysis (TEN) is a life-threatening mucocutaneous disease characterized by extensive epidermal sloughing complicated by multisystem organ dysfunction [1]. TEN is mediated by activated CD8⁺ T cells that induce keratinocyte apoptosis [1] and is most commonly attributed to drugs, such as sulfonamides, anticonvulsants, penicillin and nonsteroidal anti-inflammatory medications [2].

By comparison, hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome characterized by fevers, cytopenias, splenomegaly, decreased NK cell function, and biochemical features of excessive inflammation (Table 1). T-lymphocytes and macrophages are inappropriately activated in HLH, resulting in hemophagocytosis of blood cells in the bone marrow, widespread tissue infiltration by histiocytes, excessive cytokine release, and life-threatening multi-system organ dysfunction [3]. Although an extensive list of infectious agents, malignancies, rheumatologic and genetic conditions are associated with the development of HLH many cases have no identified trigger or confirmed genetic etiology.

Although cutaneous maculopapular rashes are described in HLH [4–9], extensive epidermal desquamative lesions are rare with only seven published cases to date (Table 2). We present a pediatric case of TEN in association with HLH, and review the literature. An increased awareness of this association is necessary, ensuring the diagnosis of HLH is considered early and urgent life-saving chemotherapy initiated.

Case
A previously healthy 17-month-old boy was hospitalized for severe laryngotracheitis, requiring 7 days of ventilatory support. Endotracheal cultures grew methicillin-sensitive Staphylococcus aureus, and nasopharyngeal aspirates positive for both parainfluenza 1 virus and rhinovirus. The patient was treated with IV cloxacillin and 5 days of dexamethasone, before being discharged home on oral cephalexin and ibuprofen.

Nine days after discharge the patient presented to the emergency department with a 5-day history of a spreading erythematous rash (Fig. 1A) and 3 days of high fevers. Examination revealed a toxic, febrile and drooling toddler, with an extensive maculopapular rash, oral mucositis and biphasic stridor. Hepatosplenomegaly was not initially present. Computed tomography scanning demon-
Over the next week the rash evolved, progressing to full desquamation of most of the patient’s body surface area. Skin biopsy confirmed the clinical diagnosis of TEN (Fig. 1B) and intravenous immunoglobulin was initiated. Either ibuprofen or cephalexin was felt to be initiating factors for the TEN. During this time, the clinical status of the patient deteriorated, with development of significant fluid third spacing, acute respiratory distress syndrome requiring increased ventilator settings, cardiovascular shock requiring inotropes and vasopressors, and a direct hyperbilirubinemia. Pancytopenia, coagulopathy and bleeding ensued, and was managed with red blood cell, plasma and platelet transfusions. Persistent temperature spikes above 38.5°C continued for 12 days after readmission to hospital.

During the progression of critical illness, all eight diagnostic criteria for HLH were met [10] despite corticosteroid use for airway edema and refractory shock. These included persistent fever ≥38.5°C, splenomegaly, cytopenias affecting all major cell lineages (lowest platelet count of 12 × 10⁹/L, lowest hemoglobin 75 g/L, lowest neutrophil count 0.02 × 10⁹/L), hypertriglyceridemia (4.3 mmol/L), and hypofibrinogenemia (0.9 g/L), unequivocal and extensive hemophagocytosis in a bone marrow aspirate (Fig. 1C), absent natural killer cell activity, hyperferritinemia (7107 μg/L; normal 20–140), and elevated soluble IL2-receptor-alpha levels (16,636 U/L; normal 334–3026 U/L). A lumbar puncture revealed no evidence of hemophagocytosis in the cerebrospinal fluid.

An extensive infectious disease evaluation revealed only the presence of human herpes virus-6 PCR positivity (3000 viral copies/mL) in the bone marrow aspirate and Candida albicans by culture from an indwelling urinary catheter. Multiple culture, serology, and PCR tests from the blood, CSF, nasopharynx, mouth, and stool for Epstein–Barr Virus (EBV), Cytomegalovirus, Herpes Simplex Virus-1 and -2, Adenovirus, Varicella virus, hepatitis A, B, C, Coxsackie virus, and respiratory syncytial virus (RSV) were negative. The patient was subsequently continued on broad spectrum antibiotics and transitioned to palliative care as the clinical course deteriorated with development of significant organ system failure and poor response to interventions, including ECMO.

Table 1. Diagnostic criteria for hemophagocytic lymphohistiocytosis (adapted [10], with units converted to SI units).

| Criteria                                                                 | SI units |
|------------------------------------------------------------------------|----------|
| A. Molecular diagnosis consistent with HLH: pathologic mutations of PRF1, UNC13D, Munc18-2, Rab27a, STX11, SH2D1A, or BIRC4 Or |          |
| B. Five of the eight criteria listed below being fulfilled:             |          |
| 1. Fever ≥38.5°C                                                       |          |
| 2. Splenomegaly                                                        |          |
| 3. Cytopenias (affecting at least 2 of 3 lineages in the peripheral blood) |          |
| Hemoglobin <90 g/L (in infants <4 weeks: <100 g/L) |          |
| Platelets <100 × 10⁹/L                                               |          |
| Neutrophils <1 × 10⁹/L                                               |          |
| 4. Hypertriglyceridemia (fasting, ≥3 mmol/L) and/or hypofibrinogenemia (<1.5 g/L). |          |
| 5. Hemophagocytosis in bone marrow, spleen, lymph nodes, or liver     |          |
| 6. Low or Absent NK cell activity                                      |          |
| 7. Ferritin ≥500 μg/L (most cases are >3000 μg/L; with >10000 μg/L being highly suspicious for HLH). |          |
| 8. Elevated soluble IL-2 receptor alpha (sCD25) ≥ 2 standard deviations from the mean for age and institution-specific normative lab values. |          |

HLH, hemophagocytic lymphohistiocytosis.

Table 2. Summary of reported cases of desquamative conditions and HLH.

| References | Age (yr) | Sex | Mucocutaneous reaction | Potential medication trigger | HLH disease association | Outcome |
|------------|----------|-----|------------------------|-----------------------------|------------------------|---------|
| Kawachi et al. [11] | 16 | F | SJS/TEN | None identified | EBV | Discharged home. Small areas of erythema and desquamation. |
| Zeng and Chen [18] | 7 months | M | SJS | Ceftriaxone | Unknown | Discharged home in good health |
| Sharma et al. [17] | 2 | F | TEN | None identified | EBV | One relapse, no permanent skin damage or developmental delay |
| Pakran et al. [19] | 12 | F | SJS/TEN | Sodium valproate | MRSA | Died on day 8. Was on dialysis, awaiting renal transplantation. |
| Fan et al. [12] | 4 | M | SJS | Ibuprofen | Unknown | Discharged home in good condition |
| Mastumoto et al. [16] | 34 | F | SJS | Antidepressants | HPV-B19 | Died due to MRSA sepsis and DIC. |
| Yamaoka et al. [13] | 76 | F | TEN | Etodolac? | Unknown | Died due to sepsis and hepatic dysfunction. |

SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; EBV, Epstein–Barr virus.
Enteroviruses, common respiratory viral pathogens, bacterial and fungal cultures were negative.

Further HLH evaluation revealed normal perforin, granzyme, SLAM-associated protein (SAP), and X-linked inhibitor of apoptosis protein (XIAP) expression by flow cytometry. A CD107a mobilization assay was also normal (mean cell fluorescence 215; normal 207–678), making genetic degranulation disorders associated with HLH less likely.

Emergent chemotherapy was initiated with etoposide and dexamethasone according to the HLH-94 protocol [10], and continued for 8 weeks. The patient made a full recovery over the next 2-months, with resolution of TEN and normalization of biochemical and hematologic parameters of HLH. No HLH genetic mutation, including mutations in UNC13D, STX11, RAB27A, and STXBP2 were found. PRF1, LYST, and x-linked lymphoproliferative disorder mutations in SH2D1A and XIAP were not performed due to normal perforin levels, absence of Che-diak-Higashi features, and normal SAP and XIAP levels, respectively. Six months after initial diagnosis, there has been no recurrence of either the TEN or HLH.

**Discussion**

We report a case of HLH in association with TEN. A definitive etiology for either disorder could not be determined, although we suspect that ibuprofen or cephalaxin may have played a role. Alternatively, we cannot discount that an infectious agent (S. aureus, parainfluenza virus, rhinovirus, or HHV-6) triggered the process. Regardless, this case illustrates that the severe, life-threatening syndrome of HLH can occur in the context of TEN, and the two disorders should not be considered mutually exclusive. Healthcare providers involved in the diagnosis and management of TEN must be aware of the possibility of concomitant HLH, particularly in cases with severe multi-organ system involvement.

Membranous desquamation prior to HLH diagnosis has been documented in case reports [11–13]. This may be a spurious observation, or herald a pivotal aspect of disease progression. Both TEN and HLH overlap in the defective activation of cytotoxic CD8+ lymphocytes and elevation of serum granulysin [14, 15]. This relation may suggest that a common process could account for both presentations. Our case describes a boy with a confirmed viral and bacterial prodrome, followed by a presumptive immune drug response. A two-hit hypothesis has support in three other cases [12, 13, 16], whereby nonspecific viral upper respiratory tract symptoms temporally overlapped with medications commonly implicated with TEN. Two other TEN cases [11, 17] reported no mucosal involvement and isolated EBV from the skin lesions, suggesting a single viral entity.
Our patient’s favorable outcome is consistent with other pediatric case reports [11, 12, 17, 18]. One patient relapsed [19], but was effectively managed, demonstrating the need for close surveillance. One fatality did occur, however [12], with a patient experiencing considerable comorbidities including chronic renal failure requiring hemodialysis. Considering that the overall pediatric mortality rate for TEN is below 30% [3], and for secondary HLH ranges between 8% and 22% [20], these reported outcomes are encouraging.

The possible relation between HLH and desquamative conditions presents at least two questions. First, how prevalent is undiagnosed HLH in fatal cases of TEN? In adults, Wolf et al. [21] and Rejaraatnam et al. [22] reported prognostic factors for TEN mortality that included severe anemia, neutopenia, lymphopenia, and visceral organ involvement. Given the overlap with these factors and HLH diagnostic criteria, these findings may suggest the presence of underappreciated HLH. Second, what is the relation between drug-induced hypersensitivity syndrome (DIHS), severe cutaneous adverse reactions and HLH? In a prospective DIHS adult cohort [23], patients presented with a constitution of symptoms including fever, hypertriglyceridemia, hyperferritinemia, pancytopenia, subtle mucosal involvement, and erythroderma with mild desquamation. Stronger associations between DIHS and confirmed HLH without desquamation have been published with antiepileptic drugs, chemotherapy, immunomodulators, and antibiotics.

Diagnosing HLH is challenging. It requires a recognition that it often occurs in the context of more defined entities such as infection, malignancy, and apparently, TEN. It also involves processing a number of nonspecific clues (e.g., hyperferritinemia, persistent fevers, cytopenias) within the diagnostic framework for HLH (Table 1). The criteria may be variably present at different time points, and affected by concomitant corticosteroid use before a HLH diagnosis is considered. Finally, the ability to perform specialized tests (NK cell function assays, soluble IL-2 receptor levels) may not readily available, even in tertiary-care hospitals.

HLH is likely underdiagnosed due to a lack of awareness about the condition, the inability to access specialized diagnostic testing, and erroneous beliefs that the disorder is exceedingly rare and that failure to identify hemophagocytosis in bone marrow aspirates rules the condition out [10]. Our center has formalized processes, including payment, for urgent specialized testing of NK cell function and soluble IL2-receptor alpha at Cincinnati Children’s Hospital’s Diagnostic Immunology Laboratory (http://www.cincinnatichildren.org/service/i/immunedeficiency/diagnostic-lab/). This, combined with early consultation to pediatric hematology-oncology, has resulted in a number of HLH diagnoses being made.

Acknowledgments

Thank you to Sate Hamza for the pathology photographs.

Conflict of Interest

None declared.

References

1. Schwartz, R. A., P. H. McDonough, and B. W. Lee. 2013. Toxic epidermal necrolysis. Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J. Am. Acad. Dermatol. 69:173.e1–173.e13.
2. Ferrandiz-Pulido, C., and V. Garcia-Patos. 2013. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch. Dis. Child. 98:998–1003.
3. Mehta, R. S., and R. E. Smith. 2013. Hemophagocytic lymphohistiocytosis (HLH): a review of literature. Med. Oncol. 30:740.
4. Henter, J., G. Elinder, O. Soder, and A. Ost. 1991. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr. Scand. 80:428–435.
5. Ariffin, H., S. H. Lum, S. A. Cheok, K. Shekhar, W. A. Ariffin, L. L. Chan, et al. 2005. Haemophagocytic lymphohistiocytosis in Malaysian children. J. Paediatr. Child Health 41:136–139.
6. Wong, K. F., and J. K. Chan. 1992. Reactive hemophagocytic syndrome – a clinicopathologic study of 40 patients in an Oriental population. Am. J. Med. 93:177–180.
7. Shirono, K., and H. Tsudo. 1995. Virus-associated haemophagocytic syndrome in previously healthy adults. Eur. J. Haematol. 55:240–244.
8. Dhote, R., J. Simon, T. Papo, B. Detournay, L. Sailler, M. H. Andre, et al. 2003. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 49:633–639.
9. Fardet, L., L. Galicier, M. D. Vignon-Pennamen, S. Regnier, M. E. Noguera, A. de Larbethe, et al. 2010. Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br. J. Dermatol. 162:547–553.
10. Jordan, M., C. Allen, S. Weitzman, A. Filipovich, and K. McClain. 2011. How I treat hemophagocytic lymphohistiocytosis. Blood 118:4041–4052.
11. Kawachi, Y., M. Itoh, Y. Fujisawa, J. Furuta, Y. Nakamura, T. Banno, et al. 2007. Epidermal cell necrosis with direct
epidermal infiltration of Epstein-Barr virus (EBV)-encoded small nuclear RNA-positive T lymphocytes in a patient with EBV-associated haemophagocytic syndrome. Br. J. Dermatol. 157:1040–1085.

12. Fan, Z. D., X. Q. Qian, and H. G. Yu. 2014. Pancytopenia as an early indicator for Stevens-Johnson syndrome complicated with hemophagocytic lymphohistiocytosis: a case report. BMC Pediatr. 14:38.

13. Yamaoka, T., H. Azukizawa, A. Tanemura, H. Murota, T. Hirose, K. Hayakawa, et al. 2012. Toxic epidermal necrolysis complicated by sepsis, haemophagocytic syndrome, and severe liver dysfunction associated with elevated interleukin-10 production. Eur. J. Dermatol. 22:815–817.

14. Lee, H. Y., and W. H. Chung. 2013. Toxic epidermal necrolysis: the year in review. Curr. Opin. Allergy Clin. Immunol. 13:330–336.

15. Nagasawa, M., K. Ogawa, S. Imashuku, and S. Mizutani. 2007. Serum granulysin is elevated in patients with hemophagocytic lymphohistiocytosis. Int. J. Hematol. 86:470–473.

16. Matsumoto, Y., D. Naniwa, S. Banno, and Y. Sugiura. 1998. Treatment of fatal hemophagocytic syndrome: two case reports. Ther. Apher. 2:300–304.

17. Sharma, N., J. Clark, H. Pham, D. Efron, D. MacGregor, R. O’Keefe, et al. 2013. TEN-like eruption in setting of EBV positive T-cell lymphoproliferative disease with HLH, in a child. Australas. J. Dermatol. 55:e44–e4.

18. Zeng, H., and X. Chen. 2009. First case report of Stevens-Johnson syndrome complicated with macrophage activation syndrome. Rheumatol. Rep. 1:30–31.

19. Pakran, J., K. Pavithran, S. Kuruvila, and M. Anand. 2013. Coexistence of Stevens-Johnson syndrome and hemophagocytic syndrome. Indian J. Paediatr. Dermatol. 14:83–87.

20. Malinowska, I., M. Machaczka, K. Popko, A. Siwicka, M. Salamonowicz, and B. Nasilowska-Adamska. 2014. Hemophagocytic syndrome in children and adults. Arch. Immunol. Ther. Exp. (Warsz) 62:385–394.

21. Wolf, R., E. Orion, B. Marcos, and H. Matz. 2005. Life-threatening acute adverse cutaneous drug reactions. Clin. Dermatol. 23:171–181.

22. Rajaratnam, R., C. Mann, P. Balasubramaniam, J. R. Marsden, S. M. Taibjee, F. Shah, et al. 2010. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin. Exp. Dermatol. 35:853–862.

23. Ben m’rad, M., S. Leclerc-Mercier, P. Blanche, N. Franck, F. Rozenberg, Y. Fulla, et al. 2009. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 88:131–140.